Andrew Cittadine - 31 Dec 2022 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Operating Officer
Signature
/s/ Kim R. Tsuchimoto, Attorney-in-fact
Issuer symbol
MNPR
Transactions as of
31 Dec 2022
Net transactions value
-$3,332
Form type
4
Filing time
03 Jan 2023, 15:07:10 UTC
Previous filing
16 Nov 2022
Next filing
03 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNPR Common Stock Options Exercise +4,062 +17% 28,300 31 Dec 2022 Direct F1
transaction MNPR Common Stock Tax liability $3,332 -1,406 -5% $2.37 26,894 31 Dec 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Restricted Stock Units Options Exercise $0 -4,062 -7.7% $0.000000 48,750 31 Dec 2022 Common Stock 4,062 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired on vesting and settlement of restricted stock units.
F2 On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.